Inovio shares jumped in pre-market trading after the FDA granted accelerated approval for Voceryq to treat adults with recurrent respiratory papillomatosis. The regulatory milestone could unlock revenue potential, though commercialization timelines remain uncertain. The stock surged roughly 230% to $1.99 before the regular session.
FDA grants accelerated approval for VOCERYQ to reduce surgeries in adults with RRP, supported by RRP-001 data showing a 27% complete response after 12 months. VOCERYQ will be available to order and ship in about 60 days, with full commercial launch targeted for Q1 2027. This milestone validates INOVIO's DNA medicines platform and could alter the standard of care for RRP patients, driving early revenue with conservative confirmatory trial expectations.
Inovio Pharmaceuticals reported fourth-quarter results that exceeded Wall Street's loss expectations, sparking increased investor interest. The company also provided positive updates regarding its lead DNA medicine candidate, which may influence future market performance and investor sentiment.
Inovio Pharmaceuticals (INO) fell 38% to $2.34. The drop followed INO's announcement of a public offering for $30 million. Sector trends show mixed performance with materials shares down by 1.1%. Overall markets showed volatility, affecting investor sentiment.